Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Reistone Reports Successful Test of JAK1 Inhibitor for Atopic Dermatitis

publication date: Oct 26, 2020

Reistone Biopharma of Shanghai reported its JAK1 inhibitor met both the primary and secondary endpoints in a China Phase II trial in patients with moderate-to-severe atopic dermatitis. At week 12, all doses of SHR0302 showed at least a 75% improvement in the Eczema Area Severity Index (EASI75) compared to placebo. Reistone in-licensed the candidate in 2018 from Jiangsu Hengrui Medicine, which backed Reistone at its founding. Reistone focuses on globalizing innovative drugs developed in China by companies like Hengrui. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital